中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页
机构
成果
学者
登录
注册
登陆
×
验证码:
换一张
忘记密码?
记住我
×
校外用户登录
CAS IR Grid
机构
上海药物研究所 [63]
昆明植物研究所 [14]
西北高原生物研究所 [10]
合肥物质科学研究院 [9]
金属研究所 [7]
成都生物研究所 [5]
更多
采集方式
OAI收割 [153]
iSwitch采集 [1]
内容类型
期刊论文 [150]
学位论文 [3]
会议论文 [1]
发表日期
2024 [1]
2023 [9]
2022 [9]
2021 [7]
2020 [6]
2019 [8]
更多
学科主题
Pharmacolo... [6]
Biochemist... [3]
Chemistry [3]
Food Scien... [3]
生命有机化学 [3]
Cell Biolo... [2]
更多
筛选
浏览/检索结果:
共154条,第1-10条
帮助
条数/页:
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
排序方式:
请选择
提交时间升序
提交时间降序
题名升序
题名降序
作者升序
作者降序
发表日期升序
发表日期降序
Development of Potent MALT1 Inhibitors Featuring a Novel "2-Thioxo-2,3-dihydrothiazolo[4,5-
d
]pyrimidin-7(6
H
)-one" Scaffold for the Treatment of B Cell Lymphoma
期刊论文
OAI收割
JOURNAL OF MEDICINAL CHEMISTRY, 2024, 卷号: 67, 期号: 4, 页码: 2884-2906
作者:
Liang, Xuewu
;
Yu, Haolan
;
Liang, Renwen
;
Feng, Zhuanghui
;
Saidahmatov, Abdusaid
  |  
收藏
  |  
浏览/下载:19/0
  |  
提交时间:2024/04/09
Design, synthesis and biological evaluation of 2-aminopyrimidine derivatives as potent FLT3 inhibitors
期刊论文
OAI收割
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2023, 卷号: 96, 页码: 5
作者:
Lian, Xuanmin
;
Gao, Yue
;
Li, Xuemei
;
Wang, Peipei
;
Tong, Lexian
  |  
收藏
  |  
浏览/下载:7/0
  |  
提交时间:2023/12/11
2-aminopyrimidine
FLT3 inhibitors
MV4-11
FLT3 mutations
Identification of [1,2,4]Triazolo[4,3-a]pyrazine PARP1 inhibitors with overcome acquired resistance activities
期刊论文
OAI收割
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2023, 卷号: 259, 页码: 19
作者:
Wang, Pingyuan
;
Zhu, Wen-Ting
;
Wang, Yajing
;
Song, Shan-Shan
;
Xi, Yong
  |  
收藏
  |  
浏览/下载:59/0
  |  
提交时间:2023/10/17
PARP1 inhibitor
Synthetic lethality
Drug resistance
Anticancer
Structure -activity relationship
Design, synthesis of auristatins-glucuronide conjugates targeting the β-glucuronidase in tumor microenvironment
期刊论文
OAI收割
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2023, 卷号: 95, 页码: 5
作者:
Wang, Yujie
  |  
收藏
  |  
浏览/下载:6/0
  |  
提交时间:2023/12/19
Auristatin E
beta-Glucuronidase
Antiproliferation
Tumor microenvironment
Exploration of novel four-membered-heterocycle constructed peptidyl proteasome inhibitors with improved metabolic stability for cancer treatment
期刊论文
OAI收割
BIOORGANIC CHEMISTRY, 2023, 卷号: 138, 页码: 22
作者:
Wang, Hanlin
;
Wu, Zhaoxiao
;
Cao, Yu
;
Gao, Lixin
;
Shao, Jiaan
  |  
收藏
  |  
浏览/下载:13/0
  |  
提交时间:2023/10/17
Metabolic stability
Four-membered heterocycles
Proteasome inhibitors
Multiple myeloma
Discovery of Novel SIRT1/2 Inhibitors with Effective Cytotoxicity against Human Leukemia Cells
期刊论文
OAI收割
JOURNAL OF CHEMICAL INFORMATION AND MODELING, 2023, 页码: 11
作者:
Cai, Haiyan
;
Wang, Yingying
;
Zhang, Jing
;
Wei, Zhenquan
;
Yan, Teng
  |  
收藏
  |  
浏览/下载:16/0
  |  
提交时间:2023/10/17
Toad venom bufadienolides and bufotoxins: An updated review
期刊论文
OAI收割
DRUG DEVELOPMENT RESEARCH, 2023, 页码: 24
作者:
Asrorov, Akmal M.
;
Kayumov, Muzaffar
;
Mukhamedov, Nurkhodja
;
Yashinov, Ansor
;
Mirakhmetova, Ziyoda
  |  
收藏
  |  
浏览/下载:9/0
  |  
提交时间:2023/10/17
arenobufagin
bufadienolides
bufalin
bufotalin
cinobufagin
cinobufotalin
gamabufotalin
Synthesis and Biological Evaluation of Sclareolide-Indole Conjugates and Their Derivatives
期刊论文
OAI收割
MOLECULES, 2023, 卷号: 28, 期号: 4, 页码: 1737
作者:
Cheng, Ying
;
Lyu, Xilin
;
Liu, Chen
;
Wang, Xiancheng
;
Cheng, Jing
  |  
收藏
  |  
浏览/下载:3/0
  |  
提交时间:2024/03/27
sclareolide
indole
polyphenol
acetal
antitumor activity
Design, synthesis, and evaluation of pyrido.[3,4-b]pyrazin-2(1H)-one derivatives as potent FLT3 inhibitors
期刊论文
OAI收割
BIOORGANIC & MEDICINAL CHEMISTRY, 2023, 卷号: 79, 页码: 117155
作者:
Sun, Mei
;
Wang, Chang
;
Wang, Peipei
;
Ye, Qingqing
;
Zhou, Yubo
  |  
收藏
  |  
浏览/下载:2/0
  |  
提交时间:2024/04/09
FLT3
FLT3-D835Y
Acute myeloid leukemia
Structure -activity relationships
Design, Synthesis, and Bioevaluation of Pyrido[2,3-d]pyrimidin-7-ones as Potent SOS1 Inhibitors
期刊论文
OAI收割
ACS MEDICINAL CHEMISTRY LETTERS, 2023, 页码: 183-190
作者:
Liu, Meiying
;
Zhou, Guizhen
;
Su, Wenhong
;
Gu, Yuejiao
;
Gao, Mingshan
  |  
收藏
  |  
浏览/下载:10/0
  |  
提交时间:2024/03/27
KRAS mutation
SOS1-KRAS interaction
SOS1 inhibitor
combination therapy